ライフサイエンスコーパス: laryngeal cancer

1 workup of patients with oral, pharyngeal, or laryngeal cancer.

2 functional preservation in locally advanced laryngeal cancer.

3 ible with IMRT and IGRT for locally advanced laryngeal cancer.

4 tration or extralaryngeal spread of advanced laryngeal cancer.

5 modify smoking and drinking odds ratios for laryngeal cancer.

6 essity for initial laryngectomy for advanced laryngeal cancer.

7 yngectomy for patients with locally advanced laryngeal cancer.

8 o identify primary and recurrent early stage laryngeal cancer.

9 t white-light endoscopy for the detection of laryngeal cancer.

10 asopharynx cancer, other pharynx cancer, and laryngeal cancer.

11 -preservation strategies in the treatment of laryngeal cancer.

12 enerally lower than those of oral cavity and laryngeal cancers.

13 studies (1981-2006) of oral, pharyngeal, and laryngeal cancers (6,772 cases and 8,375 controls) in th

14 ncurrent chemoradiation for locally advanced laryngeal cancers (8 IMRT, 19 IGRT) was undertaken.

15 For the patient with laryngeal cancer, a partial response was sustained for 1

16 benefit in local tumor control for advanced laryngeal cancers, a significant gain in regional contro

17 tomography/computed tomography (PET/CT) for laryngeal cancers after inadequate CT results.

18 s for many head and neck cancers, especially laryngeal cancers, allow for multiple treatment options.

19 nduction schedules to patients with advanced laryngeal cancer allows greater organ preservation witho

20 pplied for MALDI-MSI of N-glycans from human laryngeal cancer and ovarian cancer tissues.

21 We describe a 49-year-old man with laryngeal cancer and right pleural space infection with

22 similar trend exists, albeit less marked, in laryngeal cancers and in head and neck cancers.

23 or upfront laryngectomy in the management of laryngeal cancer are a functionless larynx and extralary

24 Laryngeal cancers are characterized by high recurrence a

25 demonstrate the major characteristics of the laryngeal cancer as expected.

26 vasive, real-time diagnosis and detection of laryngeal cancer at the molecular level.

27 older than 18 years who were diagnosed with laryngeal cancer between January 1, 1986, and December 3

28 tients with hypopharyngeal, oral cavity, and laryngeal cancers, but not for those with oropharyngeal

29 esolution 3D model of molecular marked whole laryngeal cancer by optimizing the currently available t

30 chemoradiotherapy in patients with advanced laryngeal cancer can achieve high rates of organ preserv

31 y alone in selected patients with T2-4, N0-1 laryngeal cancer can provide durable disease remission a

32 8 oro-/hypopharyngeal cancer (OHPs), and 193 laryngeal cancer cases] were available for analysis.

33 5; the Rhein-Neckar Larynx Study, a study of laryngeal cancer conducted in 1998-2000; and a lung canc

34 est risk associated with smoking observed in laryngeal cancer (current smoker hazard ratio [HR], 9.36

35 utcomes among patients having oral-cavity or laryngeal cancers even when standard disease staging was

36 underwent salvage laryngectomy for recurrent laryngeal cancer from January 1, 2000, to December 31, 2

37 reated docetaxel-resistant DRHEp2 from human laryngeal cancer HEp2 and investigated the roles of mito

38 (65/72) and specificity of 90.9% (20/22) for laryngeal cancer identification.

39 For patients investigated for laryngeal cancer in which CT is considered inadequate, d

40 Laryngeal cancer (LC) patients who meet the age and smok

41 Larynx preservation in advanced, resectable laryngeal cancer may be achieved using induction chemoth

42 Many patients with laryngeal cancer meet the formal guidelines for USPSTF s

43 ith histologically proven pancreatic cancer, laryngeal cancer, non-small cell lung cancer, prostate c

44 pattern was positively associated only with laryngeal cancer (odds ratio = 2.12, 95% confidence inte

45 mprised 45 patients investigated for primary laryngeal cancer or recurrence-residue in which CT was c

46 About two thirds of laryngeal cancers originate at the vocal cords.

47 , while smoking odds ratios were greater for laryngeal cancer (P < 0.01).

48 dependent validation cohort consisting of 63 laryngeal cancer patients.

49 For patients with stage II to IV laryngeal cancer, radiation therapy (RT) either alone or

50 In patients with laryngeal cancer, radiotherapy with concurrent administr

51 Patients with advanced laryngeal cancer received two cycles of cisplatin 100 mg

52 Significant excesses of laryngeal cancer (relative risk 7.67, based on two possi

53 sease-free survival, and overall survival in laryngeal cancer remains uncertain.

54 ttes/day varied, indicating that the greater laryngeal cancer risk derived from differential cigarett

55 Recommendations Patients with T1, T2 laryngeal cancer should be treated initially with intent

56 IR and SMR were estimated among survivors of laryngeal cancer (SIR, 1.75 [95% CI, 1.68-1.83]; inciden

57 son-years) among men, and among survivors of laryngeal cancer (SIR, 2.48 [95% CI, 2.27-2.72]; inciden

58 ; 95% confidence interval (CI): 11.3, 27.4], laryngeal cancer (SMR = 8.1; 95% CI: 3.5, 16.0), liver c

59 methylation, we for the first time identify laryngeal cancer subtypes with distinct prognostic outco

60 fold conditions or postoperative recovery of laryngeal cancer surgeries, are common causes of dysphon

61 nderstand how patients who were treated with laryngeal cancer surgery think about this later on and w

62 Participants scheduled for laryngeal cancer surgery were enrolled before surgery an

63 objectives were to study the sensitivity of laryngeal cancer to platinum-based chemotherapy alone an

64 Twelve patients with T1 or T2 laryngeal cancer underwent imaging prospectively with PE

65 herapy alone may cure selected patients with laryngeal cancer, warranting further prospective investi

66 Only 6/22 (27%) of the laryngeal cancers we examined demonstrated LOH of the BR

67 Patients with cT2-4 squamous cell laryngeal cancer were randomly assigned to AR (68 Gy wit

68 All patients with T1 or T2 laryngeal cancer, with rare exception, should be treated

69 ore individuals affected by lung, throat, or laryngeal cancer, yielded a maximum heterogeneity LOD sc